Strides Pharma FY26: EBITDA margin 19%, PAT up 40% YoY

Key takeaway for investors

Strides Pharma Science Ltd (BOM:532531) reported FY26 results showing steady improvement in revenue, profitability, and leverage. Consolidated revenue rose 6.4% year-on-year (YoY) to ₹48,587 million, while EBITDA increased 15% YoY to ₹9,250 million. The company said this was its highest-ever EBITDA and operating PAT, alongside a sustained improvement across the last 10-12 quarters. A notable operational shift in Q4 FY26 was the higher contribution from ex-U.S. markets, which contributed close to 50% of revenue. Management also highlighted ongoing investments in R&D aimed at medium and long-term growth, with benefits expected from the second half of FY27.

FY26 performance: revenue growth and stronger margins

For FY26, Strides reported consolidated revenue of ₹48,587 million, up 6.4% YoY. The company also stated that underlying growth, excluding access markets, was about 10%. Profitability improved faster than revenue, supported by margin expansion. FY26 EBITDA stood at ₹9,250 million, up 15% YoY, and the EBITDA margin expanded to 19%. The company also cited a 400 basis points expansion in EBITDA margins to 19% in FY26, and separately noted that margins expanded 140 basis points over FY25 to 19%.

Operational profit growth was sharper. Operational PAT increased 50% YoY to ₹5,180 million, crossing the ₹5,000 million mark for the first time. Reported PAT for FY26 was ₹5,750 million, up 40%, with reported EPS of ₹60.3 per share. The company also referenced an EPS of ₹56.2 per share for the year (operational basis), highlighting the difference between operational and reported metrics.

Q4 FY26: ex-U.S. contribution rises, profits improve

In the quarter ended March 31, 2026 (Q4 FY26), Strides reported revenue from operations of ₹13,234.7 million, compared with ₹11,903.9 million in the year-ago quarter. Another company disclosure cited Q4 FY26 revenue of ₹13,235 million, up 11.2% YoY, consistent with the reported total income figure.

EBITDA for Q4 FY26 was reported at ₹2,390 million, with an EBITDA margin of 18.1%. Consolidated net profit for the quarter was ₹1,292.8 million, up 51% YoY compared with ₹856 million in Q4 FY25, as described in the reported update. Operational PAT for Q4 FY26 was cited at ₹1,357 million, up 20% YoY. Total expenses in Q4 FY26 were ₹11,785.9 million versus ₹10,717.1 million in the same quarter last year.

Business mix shift: ex-U.S. markets near half of Q4 revenue

One of the clearest strategic developments highlighted by the company was geographic diversification. Ex-U.S. markets delivered robust growth and contributed close to 50% of revenue in Q4 FY26, indicating a meaningful shift in the revenue mix compared with a more U.S.-tilted profile seen historically across many Indian generic exporters.

The company also stated that ex-U.S. markets delivered 21% growth (in the context of underlying growth commentary), while it separately referenced U.S. business revenue figures for FY26 and Q4. Since the currency and basis for the U.S. revenue figures were not specified in the provided text, the key reported takeaway is the higher ex-U.S. contribution and the company’s repeated emphasis on diversification.

Deleveraging: net debt/EBITDA improves to 1.55x

Strides reported a reduction in net debt to EBITDA ratio from 1.9x to 1.55x. The company attributed this to strong cash generation and disciplined deleveraging. For investors, net debt/EBITDA is a commonly tracked indicator of balance sheet stress and funding flexibility, especially relevant for companies that run multi-geography operations and invest consistently in filings, R&D, and manufacturing capabilities.

While the company did not provide net debt in absolute rupee terms in the provided content, the direction of the ratio points to improved leverage alongside higher operating profitability.

R&D investments and what management expects next

Strides said it has made strategic investments in R&D focused on medium and long-term growth. The company expects benefits from these investments to start flowing from the second half of FY27. This guidance frames FY26 as a year of operating improvement combined with continued spending geared toward future product opportunities.

Separately, management referenced longer-term profitability objectives, including maintaining EBITDA margins of 20% and gross margins in the 58% to 60% range. These were presented as an operating aspiration alongside continued operating leverage.

Dividend and audit update

The board recommended a dividend of ₹5 per share for FY26. The company also said audited standalone and consolidated financial results for FY26 were approved, with an unmodified auditor’s opinion issued.

For the market, an unmodified audit opinion indicates the auditor did not flag material misstatements in the presented financials based on the audit procedures performed.

Snapshot table: FY26 vs Q4 FY26 key reported metrics

Why the FY26 print matters

The FY26 numbers show a familiar pattern investors look for in pharmaceuticals: modest reported top-line growth paired with stronger operating profit expansion. In Strides’ case, EBITDA rose 15% and operational PAT rose 50% even as reported revenue increased 6.4%, supported by margin expansion to 19%.

The change in geographic mix is also material. With ex-U.S. markets contributing close to half of Q4 FY26 revenue, the company is presenting a more diversified revenue base. Alongside deleveraging from 1.9x to 1.55x net debt/EBITDA, the results indicate a combination of improving operating performance and balance sheet tightening.

Conclusion

Strides Pharma Science closed FY26 with consolidated revenue of ₹48,587 million, EBITDA of ₹9,250 million at a 19% margin, and reported PAT of ₹5,750 million. Q4 FY26 reinforced the shift toward ex-U.S. markets, with ex-U.S. contributing close to 50% of quarterly revenue, while profits improved YoY. The company has flagged continued R&D investment, with expected benefits starting in the second half of FY27, and the board has recommended a dividend of ₹5 per share for FY26.